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Abstract
Background: Many patients suffering from depressive disorders are refractory to treatment with currently available
antidepressant medications, while many more exhibit only a partial response. These factors drive research to discover new
pharmacological approaches to treat depression. Numerous studies demonstrate evidence of inflammation and elevated
oxidative stress in major depression. Recently, major depression has been shown to be associated with elevated levels of DNA
oxidation in brain cells, accompanied by increased gene expression of the nuclear base excision repair enzyme, poly(ADPribose) polymerase-1. Given these findings and evidence that drugs that inhibit poly(ADP-ribose) polymerase-1 activity have
antiinflammatory and neuroprotective properties, the present study was undertaken to examine the potential antidepressant
properties of poly(ADP-ribose) polymerase inhibitors.
Methods: Two rodent models, the Porsolt swim test and repeated exposure to psychological stressors, were used to test the
poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide, for potential antidepressant activity. Another poly(ADP-ribose)
polymerase inhibitor, 5-aminoisoquinolinone, was also tested.
Results: Poly(ADP-ribose) polymerase inhibitors produced antidepressant-like effects in the Porsolt swim test, decreasing
immobility time, and increasing latency to immobility, similar to the effects of fluoxetine. In addition, 3-aminobenzamide
treatment increased sucrose preference and social interaction times relative to vehicle-treated control rats following repeated
exposure to combined social defeat and unpredictable stress, mediating effects similar to fluoxetine treatment.
Conclusions: The poly(ADP-ribose) polymerase inhibitors 3-aminobenzamide and 5-aminoisoquinolinone exhibit
antidepressant-like activity in 2 rodent stress models and uncover poly(ADP-ribose) polymerase as a unique molecular target
for the potential development of a novel class of antidepressants.
Keywords: major depression, antidepressant, PARP inhibitor
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Significance Statement
Currently available drugs for the treatment of depression have numerous limitations. Many depressed people do not respond
to these drugs, and even more people experience only a partial response. There is a crucial need to find more effective and safe
treatments for depression. The novel discovery of a class of drugs with antidepressant properties is described herein using
standard animal models used to screen drugs for antidepressant activity. The biological properties of these drugs, called PARP
inhibitors, is very different from existing antidepressants. Evidence also demonstrates that these drugs can boost the antidepressant-like effect of a traditional antidepressant.

Introduction
Conditions of elevated oxidative stress and inflammation are
proposed to play a role in the pathophysiology of major depressive disorder (MDD) as well as several psychiatric, neurological, and medical diseases (Van Gaal et al., 2006; Maes et al.,
2011; Haroon et al., 2012; Leza et al., 2015; Miller et al., 2016;
Swardfager et al., 2016). Since oxidative stress can drive inflammation and vice versa, it is likely that these 2 pathophysiological
features of MDD are interrelated. Evidence of oxidative stress
conditions in MDD include numerous demonstrations in MDD
patients of reduced plasma concentrations of free radical scavengers and elevated levels of oxidation products, including oxidized or damaged DNA (Forlenza and Miller, n.d.; Bilici et al.,
2001; Owen et al., 2005; Simon et al., 2006; Yager et al., 2010;
Maes et al., 2011). Likewise, numerous researchers have reported
elevated indices of inflammation in MDD, including C-reactive
protein, cytokines, and IgG antibodies (Howren et al., 2009; Maes
et al., 2011; Haapakoski et al., 2015). These findings raise the possibility that drugs that prevent inflammation and/or oxidative
damage may have antidepressant efficacy (Anderson and Maes,
2014; Miller et al., 2016).
Recently, elevated levels of nucleic acid oxidation have been
observed in brain white matter (Szebeni et al., 2016) and the hippocampus (Che et al., 2010) from MDD brain donors compared
with normal control brain donors. Both white matter and the hippocampus contain cells that are uniquely susceptible to oxidative
stress. In the hippocampus, these cells include CA1 pyramidal
neurons (Wang and Michaelis, 2010). In white matter, myelinating oligodendrocytes are the predominant cellular residents, and
these cells are normally susceptible to oxidative damage because
of their high rate of metabolism, high levels of iron, and relatively low levels of antioxidant enzyme expression (Kim and Kim,
1991; Connor and Menzies, 1996; Thorburne and Juurlink, 1996;
Juurlink et al., 1998). Other indicators of oxidative damage to
brain white matter in MDD include shortened telomeres, reduced
gene expression of antioxidant enzymes, and upregulation of the
gene expression of DNA base excision repair enzymes, poly(ADPribose) polymerase-1 (PARP1) and oxoguanine glycosylase, in
white matter oligodendrocytes from MDD donors (Szebeni et al.,
2014, 2016). Interruption of the damaging effects of oxidation in
white matter or other susceptible brain regions has the potential
to provide therapeutic benefit in the treatment of MDD.
The observation of upregulated PARP1 gene expression in
MDD (Szebeni et al., 2016) is particularly interesting given the
role of this enzyme in numerous cellular functions. The activity
of PARP1 is activated by strand breaks in DNA such as result from
oxidative attack of DNA bases. PARP1 uses NAD+ as a substrate
to attach poly(ADP-ribose) (PAR) polymers to proteins, including
PARP1 itself and other nuclear proteins, including histones (De
Vos et al., 2012). Through PARylation and also protein-protein
interactions, PARP1 participates in several molecular pathways,
including DNA repair, chromatin remodeling, and activation of
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NF-κB (Gibson and Kraus, 2012). Drugs that inhibit PARP1 activity have therapeutic benefit in the treatment of certain cancers,
because they increase the lethality of DNA damaging anti-cancer treatments (De Vos et al., 2012). Interestingly, PARP inhibition
or PARP1 knockout delivers antiinflammatory and/or neuroprotective effects in a variety of experimental disease conditions,
including chronic asthma (Zaffini et al., 2016), myocardial infarction (Wayman et al., 2001), stress-evoked immuno-compromise
(Drazen et al., 2001), traumatic brain injury (Besson et al., 2003),
and cerebral ischemia (Gerace et al., 2012). The finding of elevated DNA oxidation and upregulation of gene expression of
PARP1 in white matter in MDD (Szebeni et al., 2016) raises the
possibility that pharmacological inhibition of PARP1 could interfere with pathological processes that contribute to this disorder.
In light of this possibility, we (Szebeni et al., 2016) and others
(Liu et al., 1996; Sigwalt et al., 2011) have demonstrated elevated
levels of DNA oxidation in rat brain following repeated exposure to stress, showing that stressed rats may be useful for the
study of the behavioral effects of drugs that reverse downstream
effects of oxidative damage to brain cells. Since DNA oxidation
activates PARP1, which activates NF-κB and downstream inflammation, it seems reasonable to predict that PARP inhibitors may
have antidepressant properties that are detectable in rodent
stress models.
The possibility that PARP inhibitors could have therapeutic utility in the treatment of MDD is strongly supported by a
number of related studies that have not made the direct connection between PARP inhibition and antidepressant action.
Though chiefly prescribed as an antibiotic, numerous studies
have shown that minocycline mediates a beneficial neuroprotective effect with efficacy for a wide variety of diseases (Chen
et al., 2000; Tikka and Koistinaho, 2001; Nirmalananthan and
Greensmith, 2005). Interestingly, minocycline is a high affinity inhibitor of PARP-1; subsequent comparison across several
tetracycline derivatives found a strong correlation between
PARP-1 binding and neuroprotective potency (Alano et al., 2006).
Furthermore, antidepressant effects of minocycline have been
anecdotally observed in humans as well as in many studies
using rodent models (Molina-Hernández et al., 2008; O’Connor
et al., 2009; Arakawa et al., 2012; Saeedi Saravi et al., 2016). In a
study of inflammation and its behavioral consequences, treatment of rats with the PARP inhibitor 3-aminobenzamide (3-AB)
reversed depressive effects caused by lipopolysaccharide injection (Sriram et al., 2015). However, this sickness-based model for
depression arguably remains etiologically distant from causes of
MDD in humans (Stepanichev et al., 2014).
In the present study, we tested the hypothesis that PARP
inhibition will have antidepressant activity using 2 different
rodent models involving psychological stress: (1) a combined
repeated social defeat and repeated unpredictable stress model,
both models of which are used to identify antidepressant effects
(O’Leary and Cryan, 2013) and/or used to explore the biological effects of psychological stress in relation to posttraumatic
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stress disorder (Whitaker et al., 2014; Borghans and Homberg,
2015); and (2) the Porsolt swim test, commonly used to identify
antidepressant/antianxiety drugs (O’Leary and Cryan, 2013).
Two structurally different PARP inhibitors were tested: 3-AB and
5-aminoisoquinolinone (5-AIQ). Both of these drugs have been
shown to be antagonists of PARP, and both drugs have also been
demonstrated to produce neuroprotective and/or antiinflammatory actions in other disease models (Wallis et al., 1996; Hendryk
et al., 2008; Zaffini et al., 2016). The present study demonstrates
that the PARP inhibitors 3-AB and 5-AIQ have antidepressantlike activity. These findings uncover PARP as a unique molecular
target for the development of a novel class of antidepressants.

Materials and Methods
Laboratory Animals
The use of animals for this study was approved by the University
Committee on Animal Care at East Tennessee State University.
All rats were ordered from Envigo, Inc. Male Sprague-Dawley
rats (225–250 g upon arrival) were used as subjects in the
Porsolt swim test and were socially housed in groups of 2 to 3
per cage. Rats used as “intruders” in the social defeat paradigm
were individually housed and provided enrichment per the NIH
Guidelines for the Care and Use of Animals. Intruder rats were
male Sprague-Dawley rats (225–250 g). In addition, a total of 14
female Sprague-Dawley rats weighing 175 to 199 g upon arrival
were obtained for the social defeat paradigm, and these rats
were socially housed for 6 days in the animal colony prior to fallopian tube ligature, performed as previously described (Szebeni
et al., 2016). Sixteen male Long-Evans hooded rats weighing 250
to 275 g upon arrival were used as “residents” in the social defeat
paradigm. A climate-controlled vivarium was utilized, and animals were kept on a 12-h-on/12-off light/dark cycle.

Social Defeat Stress (SDS)
SDS was induced as described previously (Covington and
Miczek, 2001; Szebeni et al., 2016). Briefly, Long-Evans hooded
rats (residents) were each mated with a female (ligated) rat for a
7-day period. On the eighth day and after removal of the female,
an intruder rat was placed into the cage for a 5-minute period,
and dominance was established by the resident. Defeat was produced between 9:00 am and 10:00 am daily for 10 consecutive
days. Control rats not exposed to defeat were handled each day
during this same period.

Chronic Unpredictable Stress (CUS)
CUS was performed after SDS on the same day but at random
times either during the day or evening as previously described
(Bondi et al., 2008; Szebeni et al., 2016). Different stressors were
randomly arranged and occurred at random times during the
light or dark cycle of each day for 10 consecutive days. All rats
were exposed twice to each of 5 different stressors, which
included a 30-minute restraint, a 1-hour shaking/crowding,
10-minute cold water (18oC) swim, a 15-minute warm water
swim (25oC), and a 24-hour tipped cage. For restraint, rats were
placed in a restraining device made of Plexiglas restricting
movement but allowing free respiration and air circulation. In
the shaking-crowding procedure, 6 rats were placed in a cardboard box atop a laboratory shaker set to produce 220 backand-forth movements (approximately 2-in sideways deflection)
per minute. Both warm and cold swims were accomplished
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by placing the rat in a cylindrical tank (60 cm height × 30 cm
diameter) filled with water at a depth of 30 cm. For the tipped
cage, the animal’s home cage was tipped to one side by attaching a metal spring to one side of the cage to the cage rack for a
24-hour period. Control rats were not exposed to the stressors
but were handled each day at the same time.

Sucrose Preference
Sucrose preference was performed during the final 3 days of
induction of social defeat stress (days 8–10) using a procedure
based on that of D’Aquila et al. (1997). Animals were given 2 bottles on their cages between 7:00 pm and 9:00 pm on each day
that it was performed (the first 2 h of the dark cycle) with 1 bottle containing tap water and the other containing 0.8% sucrose.
Amounts of sucrose consumed were calculated as percentages
of the total amount of fluid consumed during the 2-hour period
on each of the 3 days of testing. The position of the sucrose bottle (left or right) was alternated equally between groups and
over days. The preference of sucrose over water was used as a
measure of an animal’s sensitivity to reward and expressed as
a percent.

Social Interaction Test
The social interaction test was performed 24 hours after the last
social defeat stress on day 11 of behavioral testing. The interaction test was conducted exactly as previously described (Brown
et al., 2011). Animals were placed into a locomotor arena that was
divided in half by a removable metal wire divider. The intruder
was first placed into the area on one side of the divider and
allowed to habituate for 5 minutes. After this period, a resident
rat was placed on the other side of the divider. The amount of
time spent in a defined interaction zone close to the metal divider
was measured using ANY-maze video tracking (Stoelting Co).

Porsolt Swim Test
Different groups of animals were tested in the Porsolt swim test.
Rats were treated using the same drug treatment regimen as
with the SDS/CUS paradigm, except as noted in the combined
drug treatments as noted in the Results. On day 8 of drug treatment, all animals began behavioral testing in the Porsolt swim
test, also known as the forced swim stress test. All animals were
tested in black cylinders measuring 36 cm in diameter, and
these cylinders were filled with 23oC to 25oC water following procedures as reviewed previously (Bogdanova et al., 2013), consistent with the original procedure of Porsolt and coworkers (Porsolt
et al., 1978). All animals were given a pre-swim exposure test on
the first day of testing, 24 hours before the swim test session the
following day. On the first day of testing, animals were exposed
to the water for 15 minutes, and on the second day were given a
5-minute trial. The 2 dependent measures used for forced swim
stress were the latency to first immobility episode (immobility lasting >5 seconds) and the total immobility time over the
5-minute period, both recorded on the second day of testing. All
movements of the animal were recorded by behavioral scanning
software (ANY-maze, Stoelting Co).

Drug Administration
All drugs used in the study, 3-aminobenzamide (product no.
A0788; 3-AB), 5-AIQ hydrochloride (product no. A7479), and fluoxetine (product no. F132), were obtained from Sigma-Aldrich, Inc.
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Statistical Analysis
A Grubb’s test was used to remove statistical outliers from each
dataset prior to analyses. Statistical analyses were otherwise
performed as indicated using IBM SPSS Statistics (version 23.0),
and data were graphed using GraphPad Prism (version 5.0b,
GraphPad Software). An independent sample t test was used to
analyze data generated when only 2 groups were analyzed. An
ANOVA was used to test multiple group comparisons. For posthoc statistical comparisons, a Bonferroni correction was applied
(as noted) to limit Type I error in multiple posthoc comparisons.
For the combined drug treatment experiment, ANOVA was followed by a Dunnett’s Multiple Comparison test that focused
comparisons of drug treatment groups with the vehicle control
group. All data are expressed as mean ± SEM.

Results
PARP Inhibitors and the Porsolt Swim Test
An initial preliminary experiment was conducted to examine
the effects of 3-AB in the Porsolt swim test. Two groups of rats
received either saline vehicle or 3-AB (40 mg/kg) s.c. daily for 10
days prior to swim testing. On the 10th day of treatment and
2 hours after drug or vehicle injections, rats treated with 3-AB
demonstrated a significantly decreased time spent immobile
compared with saline-treated controls on day 2 of the swim
test (t[14] = 2.36, P < .05) (Figure 1A). Additionally, 3-AB-treated rats
demonstrated a significant increase in the latency to immobility
(t[13] = 5.56, P < .001) (Figure 1B).
Based on these data, a more extensive experiment was conducted to examine the effect of PARP inhibitors in the Porsolt
swim test. Three doses of 3-AB (0.4, 4, and 40 mg/kg) were
selected for study that were in the approximate range of doses
shown to be effective in other disease models (Besson et al.,
2003; Zaffini et al., 2016). In addition, a second PARP inhibitor,
5-AIQ, was tested at a dose of 0.3 mg/kg i.p., a dose previously
shown to have protective properties in a rat model of myocardial infarction (Wayman et al., 2001). These treatments, and an
additional group of rats treated with saline vehicle, were administered once daily for 10 days prior to behavioral testing. Two
additional treatment groups were analyzed, including fluoxetine (10 mg/kg i.p.) and 3-AB (40 mg/kg s.c.; denoted 3-AB x
3), both groups of which received injections 23.5, 5, and 1 hour
before behavioral testing identical to the protocol followed by
Lucki and colleagues (1998). A 1-way ANOVA of immobility time
in the swim test revealed a significant main effect of treatment
group (F[6,68] = 5.55, P < .001). A posthoc Bonferroni comparison of
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the treatment groups of 5-AIQ, 3-AB 40/mg/kg (for 10 days), 3-AB
x 3, and fluoxetine was equivalent with respect to immobility
times, and rats in these groups spent significantly less time
immobile than rats in the vehicle group and in the rats treated
with the 2 lower doses of 3-AB (0.4 and 4 mg/kg) (Figure 2A). For
latency to immobility, 1-way ANOVA revealed a significant main
effect of group (F[6,68] = 9.08, P < .001) (Figure 2B). Posthoc analysis
revealed that latencies of the fluoxetine group and rats treated
with 40 mg/kg 3-AB for 10 days were equivalent and significantly
greater than all vehicle-treated control rats. The 2 lower dose
3-AB groups, the 3-AB x 3, the 5-AIQ treated group, and the vehicle control group did not significantly differ from one another.
The statistical results of all group comparisons are shown in
Supplemental Table 1.
A third experiment was performed to determine whether
3-AB would increase the antidepressant activity of fluoxetine,
again using the Porsolt swim test. Rats were treated with a dose of
3-AB (4 mg/kg; administered 3 times over 24 hours) that was not
observed in previous experiments to produce a significant effect
on immobility time or latency to immobility (see Figure 2A-B).
A dose of fluoxetine (2.5 mg/kg; administered 3 times over 24
hours) was chosen that was expected to produce a less than
maximal antidepressant response in the swim test (Broom et al.,
2002). Both drugs were also administered together at the same
doses and treatment schedule, as was saline vehicle. Analysis
of data from this experiment revealed a significant group main
effect on both immobility time (F = 4.32[3,31], P = .01; Figure 3A) and
latency to immobility (F = 5.20[3,32], P = .006; Figure 3B). A Dunnett’s
test was used to compare each drug treatment group to the
vehicle-treated group. Both 3-AB and fluoxetine alone did not
significantly affect either immobility time or latency, while the
combined treatment significantly reduced immobility (P < .01)
and significantly increased latency to immobility (P < .01).
Drugs that increase locomotor activity can produce false
positives in the Porsolt swim test. To consider the possibility
that PARP inhibitors stimulate locomotor activity, 2 measures of
activity were assessed for all rats of the second and third Porsolt
swim experiments. Swim speed was assessed during the Porsolt
swim procedure. Locomotor activity was measured in an open
field 24 hours after the second day of the Porsolt swim test, at
the same time after drug or vehicle injections as was performed
for the swim test. There were no significant group differences
in swim speed during the Porsolt swim test (F[6,67] = 1.57, P = .170;
Figure 4A) or in locomotor activity tested the following day
(F[6,67] = 0.956, P = .463; Figure 4B) in the second experiment (corresponding to Figure 2). Likewise, no significant group differences in swim speed (F[3,31] = 0.487, P = .69; Figure 4C) or locomotor
activity (F[3,31] = 1.03, P = .37; Figure 4D) were observed in the third
experiment (corresponding to Figure 3).

Figure 1. Preliminary experiment examining the effects of 3-aminobenzamide (3-AB) in the Porsolt swim test. 3-AB (40 mg/kg; n = 8) or vehicle (n = 10) was administered
s.c. daily for 10 days prior to the swim test. Swim test data were collected on the 10th day of treatment, 2 hours after drug or vehicle injection. Total time spent immobile
in the tank (A) and the latency time to immobility (B) were measured. The asterisks indicate statistical significance (*P < .05, **P < .001).
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Figure 2. Effect of poly(ADP-ribose) polymerase (PARP) inhibitors on immobility time (A) and latency to immobility (B) in the Porsolt swim test. Rats were treated daily
for 10 days prior to the swim test with either saline (vehicle i.p.: n=13), 3-aminobenzamide (3-AB) administered at 3 different doses as noted (s.c.; n=8-10), or 5-AIQ (0.3
mg/kg i.p.; n=9). Additional groups of rats were administered 3 injections over 24 hours prior to the swim test with either fluoxetine (10 mg/kg i.p. per injection; n = 10;
FLX x 3) or 3-AB (40 mg/kg s.c. per injection; n = 7; 3-AB x 3). The swim test data were collected 2 h after the final drug or vehicle injection. Asterisks indicate significant
differences compared to the vehicle group (*P < .05, **P < .01). The results of statistical analyses of all other comparisons can be found in Supplemental Table 1.

Figure 3. Effect of combined treatment of 3-aminobenzamide (3-AB) and fluoxetine (FLX) on immobility time (A) and latency to immobility (B) in the Porsolt swim
test. Rats were administered 3 injections over 24 hours prior to the swim test with either vehicle (i.p.; n=11), 3-AB (4 mg/kg s.c.; n = 7), FLX (2.5 mg/kg i.p.; n = 7), or 3-AB
(4 mg/kg s.c.) plus FLX (2.5 mg/kg i.p.; n = 6–7). The swim test data were collected 2 h after the final drug or vehicle injection. Asterisks indicate significant differences
comparing each drug-treated group with the vehicle group (*P < .01).

PARP Inhibitors and Combined and Repeated Social
Defeat and Unpredictable Stress
Experiments were performed to determine whether the PARP
inhibitor 3-AB would block the behavioral effects of repeated
psychological stress. Rats were treated with vehicle, fluoxetine (10 mg/kg i.p. daily), or 3-AB (40 mg/kg s.c. daily) 2 hours
prior to the social defeat procedure each day for 10 days. These
rats were also exposed daily to an unpredictable stressor. Rats
receiving vehicle but no exposure to the 2 daily stressors served
as a control group. ANOVA revealed a significant main effect of
group (F[3,28] = 12.91, P = 2.7 x 10–5) (Figure 5A) on sucrose preference.
Posthoc analysis showed that vehicle-treated stressed rats had
a robust reduction in sucrose preference relative to nonstressed
control rats (P = 1.1 x 10–5). Sucrose preference was significantly
higher in stressed rats treated with 3-AB (P = .024) or fluoxetine
(P = .005) compared with stressed rats treated with vehicle, while
3-AB and fluoxetine groups did not significantly differ. There
was also a significant group main effect on time spent in the
interaction zone (F[3,29] = 3.23, P = .03) (Figure 5B). Vehicle-treated
rats exposed to the stressors had a robust reduction of time
in the interaction zone compared with control rats (P = .008).
Rats treated with 3-AB and exposed to stressors exhibited
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significantly greater interaction times compared with vehicletreated rats exposed to stressors (P = .014). Interaction times of
the fluoxetine-treated rats appeared to be greater than that of
vehicle-treated rats exposed to stress, although this difference
did not reach statistical significance (P = .073). The statistical
results of all group comparisons of sucrose preference and interaction times are shown in Supplemental Table 2.

Discussion
The present study is the first to demonstrate the ability of PARP
inhibitors to counteract the deleterious effects of psychological stress on rodent behaviors and to produce antidepressantlike activity. Two structurally different PARP inhibitors, 3-AB
and 5-AIQ, demonstrated antidepressant-like activity in the
Porsolt swim test. Both 3-AB and 5-AIQ produced their antidepressant-like responses in the swim test at doses that did not
significantly affect locomotor activity or swim speed, suggesting that reduced immobility produced by these drugs was not
secondary to a stimulant effect of the compounds. In addition,
the combination of 3-AB plus fluoxetine produces antidepressant-like effects in the swim test at doses that did not produce
a significant effect for either drug when administered alone,
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Figure 4. Swim speeds (A and C) and locomotor activities (B and D) of swim test rats. A and B are data from rats of treatment groups studied in Figure 2; C and D are
data from rats of treatment groups studied in Figure 3. Swim speed was measured during the swim test, and locomotor activity was measured 24 hours after the second
day of the Porsolt swim test, both of which were measured 2 hours after drug or vehicle injection. There were no significant group effects observed for swim speed or
locomotor activity in either experiment. Sample sizes are as noted in Figures 2 and 3.

Figure 5. Effect of 3-aminobenzamide (3-AB) on sucrose preference (A) and interaction time (B) in rats exposed to repeated psychological stressors. Treatment groups
included handled control rats not exposed to stressors (Control; n = 7) and rats exposed to stressors and administered once daily injections of saline vehicle (i.p.;
Veh-Stressed; n = 7), fluoxetine (10 mg/kg i.p.; n=8), or 3-AB (40 mg/kg s.c.; n = 7). Stressed rats were exposed to social defeat and unpredictable stress each day for 10
days. Statistical results of specific group comparisons are indicated by horizontal lines above bars, with asterisks indicating significance (*P < .05, **P < .01, ***P < .0001).
Statistical results of all comparisons are provided in Supplemental Table 2.

suggesting that combination therapy is a reasonable possibility.
Finally, 3-AB protected rats from the development of anhedonia and deficits in social interaction following repeated exposure to psychological stressors. These intriguing findings open
the door to the potential development of a truly novel class of
antidepressant drugs.
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PARP1 is a key nuclear enzyme of the DNA base excision
repair apparatus that is activated by double- or single-strand
breaks, such as can occur secondary to oxidative attack of
nucleotides by free radicals. PARP1 is a member of a subfamily of 3 PARPs (PARP1, PARP2, and PARP3) that covalently build
PAR polymers onto many different proteins as a mechanism to
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regulate a variety of cellular functions. PARP1 is expressed in
many mammalian brain regions, and its gene expression in the
brain appears to be highest among the PARP1, PARP2, and PARP3
enzymes (2010 Allen Institute for Brain Science, Allen Mouse
Brain Atlas, available from http://mouse.brain-map.org). PAR
polymers are bulky and charged, and addition of PAR polymers
to nuclear proteins by PARP1 can modify protein-protein and
protein-DNA interactions. Target proteins of PARP1-mediated
PARylation include itself, histones, and transcription factors
resulting in chromatin remodeling and regulation of gene
transcription. DNA damage repair is facilitated by PARP1, but
PARP1 also facilitates NF-κB-mediated inflammatory responses
(Martínez-Zamudio and Ha, 2014), and PARP1 can directly bind
to promoter regions as a transcription factor (Ambrose et al.,
2007). Under conditions of excessive PARP1 activation, cell death
can ensue due to depletion of cellular NAD+, the substrate of
PARylation (Berger, 1985). Recent studies demonstrate that
PARP1 also has PARylation-independent effects on gene expression of inflammatory mediators (Ha et al., 2002), and it can be
activated by TNFα independently from DNA damage (Vuong
et al., 2015).
Drugs that inhibit PARP have therapeutic potential in a number of different conditions. The anti-cancer properties of PARP
inhibitors are well known. Since cancer cells exploit PARP1
to protect themselves from death secondary to DNA lesions,
PARP1 inhibitors facilitate the anti-cancer effects of DNA damaging anti-cancer drugs (e.g., cisplatin) and radiation therapy.
Numerous PARP1 inhibitors are in clinical trials for cancer and
one is currently marketed (olaparib, Astra-Zeneca, Inc.). With
regards to the ability of PARP1 to facilitate NF-κB activation,
PARP inhibitors have been recently demonstrated to have antiinflammatory and neuroprotective actions in a number of different conditions associated with inflammation, including chronic
asthma (Zaffini et al., 2016), myocardial infarction (Wayman
et al., 2001), stress-evoked immunocompromise (Drazen et al.,
2001), traumatic brain injury (Besson et al., 2003), and cerebral
ischemia (Gerace et al., 2012). In the context of the antiinflammatory effects of PARP inhibitors, there has been a recent
reemergence of interest in the role of inflammation in depressive disorders, although this continues to be a matter of debate
(Mechawar and Savitz, 2016). Elevated expression of inflammatory cytokines, IL1β and TNFα, has been observed in human
MDD patients and/or suicide victims (Shelton et al., 2011; Pandey
et al., 2012; Rizavi et al., 2016). Interestingly, inhibition of PARP1
blocks immune stimulation-induced increases in TNFα and IL1β
(Hassa and Hottiger, 2002). Although the poor affinity of 3-AB
for PARP-1 has precluded its use as a cancer therapy (Calvert
and Azzariti, 2011), its putative efficacy for treating depressive
symptoms demonstrated here suggests action through a different mechanism in which lower affinity is functional and possibly preferable. Hence, it seems possible that the ability of PARP1
inhibitors to produce antidepressant-like effects in rodents is
related to the antiinflammatory effects of these drugs, although
other possible mechanisms may be at work as well.
PARP1 is activated under conditions of elevated oxidative
stress (Liu et al., 2000; Lan et al., 2003; Adaikalakoteswari et
al., 2007), and numerous studies suggest that MDD is associated with elevated oxidative stress (Maes et al., 2011; Maurya
et al., 2016). Likewise, rodents exposed to psychological stress
demonstrate oxidative stress conditions in the brain (Che et al.,
2015; Mejia-Carmona et al., 2015; Réus et al., 2015). Because oligodendrocytes are highly sensitive to oxidative stress (Kim and
Kim, 1991; Connor and Menzies, 1996; Thorburne and Juurlink,
1996; Juurlink et al., 1998), they can be viewed as a “canary in the
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coal mine” for detecting oxidative stress conditions in the brain.
Recently, Szebeni et al. (2014, 2016) studied indices of oxidative
stress in oligodendrocytes laser captured from psychiatrically
normal and MDD brain donors. This research demonstrated
elevated levels of DNA oxidation, shortened telomeres, reduced
gene expression of antioxidant enzymes, and elevated gene
expression of PARP1 in prefrontal cortical white matter from
MDD brain donors compared with matched normal control
donors. Although PARP1 protein and activity were not measured
in that study, others have shown that PARP1 gene expression is
upregulated under oxidative stress conditions in tandem with
PARP activity levels (Adaikalakoteswari et al., 2007). Hence, these
data draw attention to the possibility that PARP1 upregulation in
MDD may contribute to cellular demise that contributes mechanistically to behavioral sequelae related to the disorder. The
ability of PARP inhibitors to produce antidepressant-like actions
in rodent behavioral models in the present study further supports the role of PARP1 in depression pathophysiology.
The rodent model of repeated stress in this study is rather
unique in that 2 stressors were administered as we have previously reported (Szebeni et al., 2016). The rationale for using
this double stress model was to reduce the likelihood of stress
resilience. Nestler and colleagues have constructed a theory of
a “neurobiology of resilience” that occurs in both rodents and
humans, wherein the rodent may be more well adapted to
develop resilience to stressors evolutionarily (Krishnan et al.,
2007; Russo et al., 2012). Since SDS is typically performed at
the same time each day, the rodent can predict over time when
the stressor will occur, possibly enhancing resilience. Humans
rarely experience stressors at the same time each day, a fact that
weakens the construct validity of SDS. We suggest that the combination of a mild (Riaz et al., 2015) stressor of unpredictable
nature (CUS) to the paradigm of SDS improves construct validity and presumably minimizes the likelihood of rats to demonstrate resilience.
PARP inhibitors have been shown to interfere with the
formation of long-term potentiation (LTP) and can disrupt
long-term memory formation in Aplysia bathed in inhibitors (Cohen-Armon et al., 2004) and in mice when inhibitors
are infused into the cerebral ventricles (Goldberg et al., 2009).
PARP knockout mice also demonstrate defects in LTP formation (Visochek et al., 2016). It is difficult to compare the levels of PARP inhibition in these studies with those achieved by
doses of PARP inhibitors administered subcutaneously or intraperitoneally to rats in the present study. It is noted that PARP
inhibitors (olaparib and niraparib) are currently FDA approved
for the treatment of specific cancers, and at the current time
reports of disruption of memory in humans taking these medications is absent in the published literature. Rather, there is
growing interest in PARP1 as a therapeutic target for the treatment of Alzheimer’s disease (Abeti et al., 2011; Martire et al.,
2015; Wang et al., 2015). The combined SDS/CUS model used
in the present study is likely to have a memory component
associated with it such that pretreatment with PARP inhibitors
could interfere with the formation of the memory of stressful
events in the model. Moreover, forced swim-induced behavioral despair (increased immobility time) requires the formation of LTP in the hippocampus (Jing et al., 2015), effects that
are blocked by NMDA receptor antagonists (ketamine, MK-801)
with known antidepressant activity (Berman et al., 2000; Trullas
and Skolnick, 1990). In fact, suppression of hippocampal LTP
has been observed following treatment of rats with several
antidepressant drugs, including trimipramine (Massicotte et al.
1993), fluoxetine (Shakesby et al., 2002; Stewart and Reid, 2000;
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Rubio et al., 2013), fluvoxamine (Kojima et al., 2003), escitalopram (Mnie-Filali et al., 2006), and milnacipram (Tachibana et
al., 2004). Hence, the potential role of LTP inhibition in mediating possible memory-disrupting effects or antidepressant-like
activity of PARP inhibitors in rats warrants further study. In
addition, direct effects of 3-AB or 5-AIQ on monoamine receptors or transporters have not been described. Although neither
3-AB nor 5-AIQ are catecholamine like or tryptamine like, an
exploration of potential secondary effects of these drugs on
biological amines will be important to clarify the mechanism
of their antidepressant-like activity.
Inadequate or incomplete treatment of MDD using currently available antidepressant drugs is a major health and
economic issue (Thase, 2009). Unfortunately, antidepressants
that are newer to the market have not substantially mitigated
this problem, because these new drugs do not demonstrate a
significantly greater therapeutic efficacy than older drugs, with
minor exceptions (Montgomery et al., 2007; Papakostas et al.,
2007). Given therapeutic shortcomings of current antidepressants, it is imperative that novel drug targets be identified to
improve the efficacy of existing antidepressants through adjuvant treatments or provide therapeutic alternatives to the
many who do not respond. The use of ketamine represents the
first noteworthy recent advance in the field, although some
major concerns remain about its efficacy (Murrough, 2016),
side effects, and its potential for diversion (Sassano-Higgins
et al., 2016). The primary actions of current commonly prescribed antidepressants involve modulation of the transmission of noradrenergic and serotonergic neurons. The present
study demonstrates antidepressant-like behavioral effects of
PARP inhibitors in 2 different animal models used typically
to screen drugs for antidepressant activity in humans. Given
that PARP inhibitors have no known direct effects on brain
norepinephrine or serotonin, the findings here strongly implicate PARP inhibitors as an entirely novel type of antidepressant. Results here also suggest that PARP inhibitors could be
used as an adjuvant to existing antidepressant treatments. The
potential use of PARP inhibitors as antidepressants in humans
will require that adequate safety testing is completed, particularly focusing on potential toxicities of these compounds
that could result from interfering with the multiple cellular
systems that are impacted by these drugs (Passeri et al., 2016).
The mechanisms involved in antidepressant-like effects of the
PARP inhibitors that were tested are presumed to be mediated
primarily through inhibition of PARP. The role of secondary
effects of PARP inhibitors in antidepressant actions, for example, suppression of LTP, antiinflammatory effects, protection
from oxidative stress-induced NAD+ depletion, and potential
effects on monoamine or glutamate transmitters, remain to be
determined.
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